Patents Assigned to Poxel SA
  • Deuterium-enriched pioglitazone
    Patent number: 11918567
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: February 3, 2021
    Date of Patent: March 5, 2024
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 11918569
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 5, 2024
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Methods of synthesizing enantiopure deuterium-enriched pioglitazone
    Patent number: 11767317
    Abstract: The invention provides methods of synthesis of enantiopure deuterium enriched R-pioglitazone with structure of compound (IV), or a pharmaceutically acceptable salt thereof: The invention further provides chemical intermediates useful in the synthesis of compound (IV), and methods of synthesizing those intermediates.
    Type: Grant
    Filed: June 28, 2021
    Date of Patent: September 26, 2023
    Assignee: Poxel SA
    Inventors: Laure Françoise Valérie Navarre, Vincent Jacques, Sébastien Bolze
  • Methods of treating heart failure with preserved ejection fraction
    Patent number: 11617754
    Abstract: The present invention provides a method for treating or preventing heart failure with preserved ejection fraction (HFPEF), wherein the method comprises administering to a patient having or at risk of developing HFPEF a therapeutically effective amount of imeglimin.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 4, 2023
    Assignee: Poxel SA
    Inventor: Sophie Hallakou-Bozec
  • Crystalline forms of deuterium-enriched pioglitazone
    Patent number: 11319313
    Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: May 3, 2022
    Assignee: Poxel SA
    Inventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
  • Methods of treating subjects having diabetes with chronic kidney disease
    Patent number: 11266652
    Abstract: The present disclosure is directed to a method of treating prediabetes or type 1 or type 2 diabetes mellitus comprising administering to a subject in need thereof an effective amount of imeglimin, wherein the subject has chronic kidney disease.
    Type: Grant
    Filed: March 9, 2020
    Date of Patent: March 8, 2022
    Assignee: POXEL SA
    Inventors: Bill Symonds, Steve Piscitelli, Karen Segal, Ruby Holder, Sophie Bozec, Sebastien Bolze, Pascale Fouqueray, Christophe Arbet-Engels, Julie Dubourg, Paul Strumph, Brandon Dale Swift, Margaret Smith Fletcher
  • Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
    Patent number: 11141411
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 12, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 11123336
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 21, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Deuterium-enriched pioglitazone
    Patent number: 10940143
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: March 9, 2021
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • Deuterium-enriched pioglitazone
    Patent number: 10576071
    Abstract: The present application describes deuterium-enriched pioglitazone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: March 3, 2020
    Assignee: Poxel SA
    Inventor: Anthony W. Czarnik
  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 10265305
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: April 23, 2019
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg